ArticleSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2025
Patterns of medication use following breast cancer diagnosis: an Australian population-based study.
Article in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThis study aimed to examine patterns of medication use and polypharmacy following breast cancer diagnosis.
methodsThis retrospective cohort study used breast cancer data from the South Australian Cancer Registry linked with medication dispensing records, death registry, and inpatient hospital records. Women diagnosed with invasive breast cancer between July 2012 and March 2014 were followed for 5 years from diagnosis. All medications were defined using the Anatomical Therapeutic Chemical classification, and patterns of use were analysed in one-yearly intervals. The changes in the use of medications and polypharmacy (≥ 5 concomitant medications versus not) from Year-2 to Year-5 of breast cancer diagnosis were examined using generalised estimating equations models with binary logistic distribution.
resultsThe study included 2005 women (mean age = 61.1 years). The use of endocrine therapy for breast cancer decreased over time (odds ratio (OR) 0.88; 95%CI = 0.86-0.90). In contrast, the likelihood of being dispensed specific cardiovascular medicines increased with each successive time period including agents acting on renin-angiotensin system (OR 1.03; 95%CI = 1.01-1.05), lipid-modifying agents (OR 1.06; 95%CI = 1.03-1.08), beta-blockers (OR 1.08; 95%CI = 1.04-1.11), and cardiac therapy (OR 1.12; 95%CI = 1.06-1.18). There was an increased likelihood of polypharmacy over time (OR 1.08; 95%CI = 1.04-1.11) with the prevalence ranging from 25% (Year 2) to 29% (Year 5). Several characteristics were associated with polypharmacy including older age, a lower socioeconomic status, and a higher burden of comorbidities.
conclusionThe use of several medication classes increased over time suggesting development of new comorbidities and higher likelihood of polypharmacy. Medication management in breast cancer survivors offers potential to identify those with complex needs of polypharmacy and comorbidity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.